Univ8 Genomics

What Univ8 Genomics does

Univ8 Genomics Ltd is a Northern Ireland-based, privately held genomics company that designs, manufactures, and commercialises targeted next-generation sequencing (NGS) assay kits for clinical cancer research, with a primary focus on hematological malignancies. The company was founded in 2019 and operates from Belfast (63 University Road, C/O QUBIS, BT7 1NF), with a headcount in the 11-50 range. Its commercial portfolio consists of two products: the EuroClonality-NDC assay (launched 2021, co-developed with the EuroClonality-NGS working group) for integrated detection of immunoglobulin and T-cell receptor rearrangements, translocations, sequence variants, and copy number alterations in lymphoproliferative disorders; and the Myeloid-NDC assay (launched February 2024) for the integrated detection of translocations, copy number variants, and sequence variants in myeloid malignancies (AML, MDS, MPN). Both assays share a single universal wet-lab protocol designed to support up to eight bespoke assays, enabling a 2-day laboratory workflow and 1-day analysis turnaround with DNA input as low as 100 ng.\n\nThe company is differentiated by its domain specialisation in hematopathology and its ties to the EuroClonality-NGS working group, an independent subdivision of EuroClonality that provides scientific authority and access to a multi-centre European validation network spanning 13 clinical and academic laboratories across the UK, Germany, Czech Republic, Italy, Spain, France, the Netherlands, and Greece. Univ8 sells directly to clinical and academic hematopathology laboratories and myeloid malignancy testing laboratories through a sales-led, direct engagement model; pricing is quote-based, not publicly disclosed, and structured around multi-year contracts with companion resources (Quick Reference Guides, Analysis Guides, sample sheet templates, MSDS, demo files). Revenue is generated from one-time licence sales of proprietary kits, with the company describing its customer base as research networks and cooperative groups (e.g., EU-MCL) in addition to individual labs.\n\nThe company has stated a development pipeline extending beyond hematology into solid tumours, sarcomas, and CNS tumours. It received early-stage funding from QUBIS (the Queen's University Belfast spin-out vehicle) in 2022, and carries a "Research Use Only; not for use in diagnostic procedures" label on its products. No public revenue, headcount trend, or ownership structure has been disclosed.

Name

Univ8 Genomics

Legal name

Univ8 Genomics Ltd

Website

https://univ8genomics.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Univ8 Genomics is a Belfast-based, privately held developer of targeted NGS assay kits for clinical cancer research, commercialising integrated hematology assays (EuroClonality-NDC and Myeloid-NDC) to clinical and academic laboratories across Europe through direct, quote-based enterprise sales.

Ownership category

akta.pro rank

Product category

Clinical Molecular Diagnostics / Cancer Genomics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Cancer diagnostics
• NGS assay kits
• Clinical genomics
• Molecular diagnostics
• Hematological malignancies

Headquarters

HQ city

Belfast

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. NGS Assay Products: Sale of proprietary EuroClonality-NDC and Myeloid-NDC assay kits for clinical cancer research. These are bespoke NGS solutions for detecting genomic alterations in hematological malignancies. Revenue is generated through direct product sales to clinical and academic laboratories.
2. Companion Resources and Documentation: Sale or distribution of assay-related resources including Quick Reference Guides, Analysis Guides, sample sheet templates, Material Safety Data Sheets, and demo files for the EuroClonality-NDC and Myeloid-NDC assays.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Univ8 Genomics manufactures and sells bespoke Next Generation Sequencing (NGS) assay kits for clinical cancer research, with a focus on hematological malignancies. Its portfolio includes the EuroClonality-NDC assay (for lymphoproliferative disorders) and the Myeloid-NDC assay (for AML, MDS, and MPN), all run on a single universal protocol that supports up to 8 bespoke assays with 2 days of laboratory work and 1 day of analysis.

Product overview

Univ8 Genomics offers a universal NGS workflow platform supporting up to 8 bespoke assays, unified under a single 1 universal protocol, 2 days laboratory work, and 1 day analysis. The portfolio consists of two commercialized core products: (1) the EuroClonality-NDC assay, the company's first product launched in 2021, designed for lymphoproliferative disorders and developed by the EuroClonality-NGS working group; and (2) the Myeloid-NDC assay, launched in February 2024 as the company's first 2024 product, targeting myeloid malignancies (AML, MDS, MPN). Both assays deliver integrated genomic profiling (rearrangements/translocations, mutations, and copy number variants) from a single DNA sample. The company is developing additional assays for solid tumours, sarcomas, and CNS tumours.

Differentiator

Problem solved

Functional benefit

Brands

• EuroClonality-NDC: NGS assay for detecting immunoglobulin and T cell receptor rearrangements, translocations, mutations and copy number alterations in lymphoproliferative disorders.
• Myeloid-NDC

Products and services

• EuroClonality-NDC assay Next-generation sequencing (NGS) assay for the detection of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements, chromosomal translocations, sequence variants, and copy number alterations in lymphoproliferative disorders. A single integrated test covering clonality assessment, mutation profiling, and copy number analysis, sold as a kit to clinical and academic hematopathology laboratories.
• Myeloid-NDC assay Next-generation sequencing (NGS) assay for the integrated detection of chromosomal translocations, copy number variants (CNV), and sequence variants in myeloid malignancies including AML, MDS, and MPN. Validated for use with high molecular weight (HMW) genomic DNA from just 100 ng of DNA input, sold as a kit to clinical laboratories specializing in myeloid malignancy diagnostics.

Quantifiable outcome

• >95% analytical sensitivity for CNV and structural variants
• +7 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• EuroClonality-NGS Working GroupcoreStrategic or Co-development PartnerThe EuroClonality-NDC assay was designed and developed by the EuroClonality-NGS working group, an independent subdivision of EuroClonality. This is a co-development partnership where the working group provides scientific expertise in immunogenetics and lymphoproliferative disorders while Univ8 commercializes the assay.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• ArcherDX (Invitae): ArcherDX, now part of Invitae, offers NGS-based assays for hematological malignancies including fusion and variant detection. Most directly comparable peer given product overlap with Univ8's EuroClonality-NDC and Myeloid-NDC assays in hematopathology.
• Invivoscribe: Invivoscribe develops and commercializes IVD and RUO NGS-based clonality and somatic mutation assays for lymphoma, leukemia, and myeloma, including the LymphoTrack and IGH/IGK assays. Directly competes in the same hematopathology clonality and MRD testing space as EuroClonality-NDC.
• Adaptive Biotechnologies: Adaptive's clonoSEQ assay is an FDA-cleared NGS test for minimal residual disease in ALL, MM, and CLL using IG receptor rearrangements. Most comparable hematology MRD competitor to EuroClonality-NDC and a benchmark for Univ8's eventual IVD pathway.
• SOPHiA Genetics: SOPHiA Genetics offers cloud-based NGS analysis and assay panels including for hematological malignancies. Competes on the bioinformatics and integrated workflow layer that complements or substitutes for Univ8's universal protocol value proposition.

Broad incumbents

• Illumina: Illumina is the dominant NGS instrument and reagent supplier whose platforms (e.g., NextSeq, NovaSeq) underlay most clinical NGS assays including Univ8's. Broad incumbent that could enter hematopathology panels directly or via partner enablement programs.
• Thermo Fisher Scientific: Thermo Fisher offers the Ion Torrent NGS platform and the Oncomine hematology assay portfolio. Broad incumbent competing both at the platform level and in hematological malignancy NGS panels.
• QIAGEN: QIAGEN provides sample-to-insight NGS workflows for clinical research including the QIAseq targeted panels. Broad incumbent offering overlapping hematology and oncology NGS solutions with established global distribution.
• Eurofins Genomics: Eurofins Genomics is a major European provider of genomic services and kits with deep reach into European clinical and academic laboratories. Relevant peer for distribution reach and competing NGS service offerings in Europe.
• Genewiz (Azenta Life Sciences): Genewiz, now part of Azenta, provides NGS services and assay development for academic and clinical customers including hematological research applications. Comparable in offering research-grade NGS services and custom assay development in Univ8's core European academic customer segment.

Emerging players

• Natera: Natera's Signatera assay is a tumor-informed ctDNA MRD test used across solid tumors and hematological malignancies. Emerging player in MRD monitoring that competes with Univ8's liquid biopsy/MRD use cases for hematology customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Univ8 Genomics